148. Imipenem-Relebactam activity and genotypic characteristics of Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa Isolates from Latin American Infections - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017 – 2020

BACKGROUND: Imipenem/relebactam (IMI/REL) is a combination of Imipenem with Relebactam, an inhibitor of class A and C β-lactamases and has been approved in the US and EU, but not in Latin America. This report evaluates the in vitro activity of IMI/REL and comparators against Latin America (LATAM) En...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Gustavo, Polis, Thales, Ferrari, Jacqueline, Pavia, Jacqueline, Beirão, Elisa, Gales, Ana C, Tuon, Felipe, Alcantara, Alexandre, Batista, Paula M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752025/
http://dx.doi.org/10.1093/ofid/ofac492.226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752025/
http://dx.doi.org/10.1093/ofid/ofac492.226

Ejemplares similares